Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient

Contraception

Volumn 60, Issue 1, 1999, Pages 51-53

  Fong, Yoke Fai ^a   Singh, Kuldip ^a  

^a NONE

Author keywords

Levonorgestrel releasing intrauterine system; Menorrhagia; Myoma; Renal transplant

Indexed keywords

ANTIANEMIC AGENT; GONADORELIN DERIVATIVE; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LEVONORGESTREL; MEFENAMIC ACID; STEROID;

ADENOMYOSIS; ADULT; ARTICLE; CANCER INHIBITION; CASE REPORT; DRUG EFFECT; DRUG RELEASE; DYSMENORRHEA; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; KIDNEY GRAFT; MENORRHAGIA; TUMOR VOLUME; UTERUS MYOMA;

BIOLOGY; CANCER; CASE STUDIES--WOMEN; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DISEASES; ENDOMETRIAL CANCER; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; IUD; IUD, HORMONE RELEASING; LEVONORGESTREL; MENORRHAGIA; MENSTRUATION DISORDERS; NEOPLASMS; PHYSIOLOGY; RENAL EFFECTS; RESEARCH METHODOLOGY; STUDIES; UROGENITAL EFFECTS; UROGENITAL SYSTEM; UTERINE EFFECTS; UTERUS; WOMEN;

ADULT; BLOOD TRANSFUSION; CONTRACEPTIVE AGENTS, FEMALE; DYSMENORRHEA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; KIDNEY TRANSPLANTATION; LEIOMYOMA; LEVONORGESTREL; MENORRHAGIA; OVARY; UTERINE NEOPLASMS; UTERUS;

EID: 0032745104     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00061-X     Document Type: Article

References (11)

1. Sivin I., Stern J. Health during prolonged use of levonorgestrel 20 μg/d and the copper TCu 380 Ag intrauterine contraceptive devices a multicenter study . Fertil Steril. 61:1994;70-73.
2. Donnez J., Nisolle M. Hysteroscopic surgery. Curr Opin Obstet Gynecol. 4:1992;439-446.
3. Milsom I., Andersson K., Andersch B., Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 164:1991;879-883.
4. Fedele L., Bianchi S., Raffaelli R., et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 68:1997;426-429.
5. Rein M.S., Barbieri R.L., Friedman A.J. Progesterone a critical role in the pathogenesis of uterine myomas . Am J Obstet Gynecol. 172:(1 Pt 1):1995;14-18.
6. Salmi A., Pakarinen P., Peltola A.M., Rutanen E.M. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod. 4:1998;1110-1115.
7. Critchley H.O., Wang H., Kelly R.W., et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 13:1998;1210-1217.
8. Fujimoto J., Hirose R., Ichigo S., et al. Expression of progesterone receptor form A and B mRNAs in uterine leiomyoma. Tumour Biol. 19:1998;126-131.
9. Rutanen E.-M., Salmi A., Nyman T. mRNA Expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod. 3:1997;749-754.
10. Pekonen F., Nyman T., Lahteenmaki P., et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab. 75:1992;660-664.
11. Giudice L.C., Irwin J.C., Dsupin B.A., et al. Insulin-like growth factor (IGF), IGF binding protein (IGF BP), and IGF receptor gene expression and IGF BP synthesis in human uterine leiomyomata. Hum Reprod. 8:1993;1796-1806.